Products
Preparation registered in Ukraine
Modern antiplatelet therapy in patients with cardiovascular diseases
I.I. Kobza, T.B. Rudyk, T.I. Kobza
Lviv National Medical University
Lviv Regional Hospital
Summary.
Contemporary approach to antiplatelet therapy for cardiovascular diseases involves the use of several drugs means of different mechanisms blocking activity of platelets. The development of such a strategy is based on the long search for effective and safe drugs with antiplatelet action selection and combinations thereof.
The authors performed the review of the modern world literature that takes the experience of using the various options antiplatelet therapy in patients with cardiovascular diseases.
Frequent development of resistance to aspirin and clopidogrel in need find new safe and effective antiplatelet agents. Cilostazol - virtually the only drug that has a large evidence base for the treatment of intermittent claudication. A number of studies on Cilostazol demonstrates advantages over other antiplatelet drugs on prevention of restenosis after both reconstructive surgery on the arteries, and stent implantations. The positive effect of this drug on the progression of atherosclerosis and secondary prevention of cardiovascular events (myocardial infarction, stroke) , the effects of a stroke, critical limb ischemia and lipid metabolism requires further study.
Key words: antiplatelet therapy, cardiovascular disease, cilostazol.